Rationale for inhibition of growth hormone secretion in the management of the diabetic patient.
Patients with diabetes mellitus, especially the insulin-dependent variety, have increased circulating levels of growth hormone. On the basis of currently available information, the potential advantages of inhibition of growth hormone secretion as an adjunct in the treatment of diabetes mellitus include improved metabolic control (less hyperglycaemia, greater stability), resulting from diminution of the insulin-antagonistic actions of this hormone, and reduced micro- and possibly macro-angiopathy, resulting not only from improved metabolic control but also from decreased direct effects of growth hormone on blood vessels.
D003920:Diabetes Mellitus / Q000188:drug therapy / Q000503:physiopathology*; D003922:Diabetes Mellitus, Type 1 / Q000188:drug therapy / Q000503:physiopathology; D003924:Diabetes Mellitus, Type 2 / Q000188:drug therapy / Q000503:physiopathology; D003930:Diabetic Retinopathy / Q000209:etiology / Q000517:prevention & control; D013006:Growth Hormone / Q000378:metabolism*; D006801:Humans; D007328:Insulin / Q000627:therapeutic use; D013004:Somatostatin / Q000031:analogs & derivatives / Q000627:therapeutic use
D007328:Insulin; D013004:Somatostatin; D013006:Growth Hormone